Novo’s Wegovy to Reach 1.2 Million More Patients in England

Novo Nordisk A/S’s obesity drug Wegovy will be an option for about 1.2 million more patients in England’s National Health Service, after the drug price regulator recommended it to prevent heart attacks and strokes.

The decision will significantly expand access to Wegovy on the state-run NHS, where the blockbuster drug is currently available through specialist weight-management services, limiting its uptake. The National Institute for Health and Care Excellence is now recommending it for overweight patients who have had a heart attack or stroke, or have serious circulation problems in their legs.